Yubo International Biotech Limited
YBGJ
$0.01
-$0.01-37.09%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 254.29% | -100.00% | -100.00% | -100.00% | -99.43% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 254.29% | -100.00% | -100.00% | -100.00% | -99.43% |
| Cost of Revenue | -98.03% | -101.94% | -61.34% | 135.71% | 13.14% |
| Gross Profit | 103.92% | 102.20% | -135.44% | -157.93% | -149.71% |
| SG&A Expenses | -19.21% | -14.14% | 7.33% | 20.32% | 11.83% |
| Depreciation & Amortization | -3.06% | -31.37% | -28.32% | -20.09% | -3.58% |
| Other Operating Expenses | -60.40% | -80.86% | -55.71% | -2.45% | 9.55% |
| Total Operating Expenses | -33.26% | -36.46% | -14.28% | 17.00% | 9.96% |
| Operating Income | 33.77% | 35.69% | -11.36% | -58.41% | -65.61% |
| Income Before Tax | 33.75% | 35.70% | -11.33% | -58.37% | -65.83% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 33.75% | 35.70% | -11.33% | -58.37% | -65.83% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -47.34% | 3.14% | 50.00% | 539.44% | -- |
| Net Income | 32.17% | 38.47% | -8.51% | -46.02% | -48.55% |
| EBIT | 33.77% | 35.69% | -11.36% | -58.41% | -65.61% |
| EBITDA | 36.90% | 36.28% | -19.51% | -75.20% | -78.64% |
| EPS Basic | 79.35% | 78.22% | 68.33% | 60.82% | -335.35% |
| Normalized Basic EPS | 79.13% | 78.73% | 68.62% | 61.80% | -303.17% |
| EPS Diluted | 79.35% | 78.22% | 68.33% | 60.82% | -335.35% |
| Normalized Diluted EPS | 79.13% | 78.73% | 68.62% | 61.80% | -303.17% |
| Average Basic Shares Outstanding | 50.30% | 36.58% | 29.03% | 29.03% | -22.50% |
| Average Diluted Shares Outstanding | 50.30% | 36.58% | 29.03% | 29.03% | -22.50% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |